GlassScriptPhysician profile
David M Sagransky
NPI 1861437717
$8,243.34
in general payments reported to CMS, 2019-2025
19 companies · $715 in 2025
The $715 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $1,070 · 2021: $1,256 · 2022: $1,338 · 2023: $1,323 · 2024: $1,059 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.78 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,439.55 | 2019-2025 | Enbrel, Evenity, Otezla |
| Abbvie INC. | $1,968.67 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,404.95 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $596.98 | 2019-2025 | |
| Lilly USA, LLC | $569.49 | 2019-2024 | Taltz, Olumiant |
| Ucb, INC. | $368.29 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $265.64 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $150.66 | 2019-2022 | |
| Genentech USA, INC. | $129.27 | 2019-2020 | |
| Sandoz INC. | $61.82 | 2023-2025 | Hyrimoz |
| Sobi, INC | $61.37 | 2020-2021 | |
| Pacira Therapeutics, INC. | $50.82 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $44.42 | 2023-2024 | Idacio |
| Genzyme Corporation | $36.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.60 | 2023-2024 | Cyltezo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $26.90 | 2019 | |
| Depuy Synthes Sales INC. | $14.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sagransky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.